Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.

Yingying Du, Yuhua Xu, Jin Feng, Longbo Hu, Yanan Zhang, Bo Zhang, Weili Guo, Runming Mai, Liyun Chen, Jianmin Fang, Hui Zhang, Tao Peng

Vaccine 2021 Apr 15

filter terms:

The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design. Copyright © 2021. Published by Elsevier Ltd.

Citation

Yingying Du, Yuhua Xu, Jin Feng, Longbo Hu, Yanan Zhang, Bo Zhang, Weili Guo, Runming Mai, Liyun Chen, Jianmin Fang, Hui Zhang, Tao Peng. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse. Vaccine. 2021 Apr 15;39(16):2280-2287